Lucentis® Prefilled Syringe for Intravitreal Injection

What Lucentis® Is and How It Works

Lucentis Prefilled Syringe is a single-use, intravitreal form of ranibizumab, an anti-VEGF biologic for retinal disease. It treats wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We partner with vetted pharmacies to supply authentic brand medications with a broad selection and value-focused pricing. Many patients compare options like Lucentis Prefilled Syringe without insurance when considering treatment access.

Ranibizumab binds vascular endothelial growth factor A (VEGF-A). This blocks abnormal blood vessel growth and leakage under the retina. Reducing leakage and neovascularization helps stabilize or improve vision. The prefilled syringe delivers the labeled dose in 0.05 mL for consistent administration by an eye care professional.

Typical dosing is monthly at the start. Some patients then transition to a treat-and-extend or as-needed schedule under clinician guidance. Indication and strength determine the exact regimen. For background on conditions, see Wet Age Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. You can also review our article Lucentis Uses Side Effects Dosage for more detail.

Dosage and Usage

• Indications and strengths: Prefilled syringes are available in labeled doses appropriate for conditions such as wet AMD, DME/DR, RVO-related macular edema, and mCNV. The dose is delivered as 0.05 mL intravitreally.
• Initiation: Many patients start with monthly injections. Clinicians may give three monthly doses, then continue monthly, treat-and-extend, or as-needed based on vision and OCT findings.
• Ongoing regimen: Visit intervals are adjusted to maintain vision and keep fluid controlled. The exact plan depends on the diagnosis and response.
• Missed dose: The clinic will reschedule the next available appointment. Doses are not doubled to make up for a missed visit.
• Administration: For intravitreal use only by qualified eye care professionals under aseptic conditions, with appropriate anesthesia and antisepsis.
• Device steps (professional use): Inspect the syringe and solution. Attach a sterile injection needle per the Instructions for Use. Expel air and set the dose to 0.05 mL using the marked dose line. Do not mix with other products.
• Injection site: Typically 3.5–4.0 mm posterior to the limbus in the inferotemporal quadrant. Monitor perfusion of the optic nerve head and intraocular pressure after injection as directed in labeling.
• Single-use only: Discard any unused product or residual fluid after injection.
• Alternate formats: Some clinics prefer vials. See Product Lucentis Vial 10mg Ml 0 23 Ml for details.

• Storage: Refrigerate at 2–8°C (36–46°F). Do not freeze. Protect from light. Keep in the original carton until use.
• Transport: Use an insulated container with cold packs to maintain 2–8°C. Avoid direct contact between the syringe and ice packs. Do not shake.
• Room temperature: If needed before a scheduled injection, limited room-temperature holding (not above 25°C/77°F) for a short period, such as up to 24 hours, may be permitted per labeling. Return to refrigeration as soon as feasible.
• Handling: Single-use sterile syringe. Do not re-sterilize. Do not use if the package is opened, damaged, or expired.
• Travel: Plan clinic appointments in advance. Keep product cold during transit. Confirm storage on arrival at the clinic.

Benefits and Savings

Clinical trials showed improved best-corrected visual acuity, reduced central retinal thickness, and less subretinal and intraretinal fluid. Many patients gain letters of vision and reduce the risk of moderate vision loss. Stabilizing the macula can support daily tasks like reading and face recognition.

The prefilled syringe helps streamline clinic workflow. It reduces preparation steps versus drawing from a vial and supports consistent dosing. The single-use design also reduces waste. Patients and clinicians can incorporate treat-and-extend strategies once the retina is dry and stable, if appropriate.

Canadian sourcing can offer strong value. Many customers save 60–80% vs typical U.S. prices. This can lower out-of-pocket costs for Lucentis Prefilled Syringe without insurance compared with some local cash prices. See our promotions page for current offers, including any Lucentis Prefilled Syringe coupon if available.

Side Effects and Safety

• Common effects: Conjunctival hemorrhage, eye pain, vitreous floaters, intraocular pressure rise shortly after injection, ocular irritation or foreign body sensation, and nasopharyngitis.
• Less common: Intraocular inflammation, corneal edema, cataract progression, photopsia, tearing, and injection-site discomfort.
• Systemic: Headache or hypertension can occur. Arterial thromboembolic events, including stroke or myocardial infarction, are rare but reported with intraocular anti-VEGF therapy.

Serious ocular risks include endophthalmitis, retinal detachment, retinal tear, traumatic cataract, significant intraocular inflammation, and sustained intraocular pressure elevation. Do not use in patients with active ocular or periocular infections, or with active intraocular inflammation. Hypersensitivity reactions can occur. Clinicians use sterile technique and provide follow-up for signs of infection or inflammation. Discuss pregnancy and breastfeeding considerations with a healthcare professional.

Onset Time

Many patients notice early anatomical improvements within weeks as macular fluid decreases. Vision gains often begin in the first month and build over the initial 1–3 months with monthly dosing. In DME and DR, gains may accrue over several months. RVO-related macular edema can respond quickly, with vision improvements often seen after the first few injections. Maintenance intervals may extend after stability is achieved.

Compare With Alternatives

Several anti-VEGF options are available for similar retinal conditions. Choice depends on diagnosis, dosing goals, prior response, and clinician preference.

Eylea® (aflibercept)

Eylea is another anti-VEGF agent used for wet AMD, DME/DR, and RVO-related macular edema. Many regimens use three monthly doses, then every 8 weeks, with possible treat-and-extend. Some clinics prefer fewer visits if stability is maintained. Compare details on Eylea.

Beovu® (brolucizumab)

Beovu offers a potential 8–12 week interval in selected patients after loading. Post-marketing experience highlights a risk of intraocular inflammation and retinal vasculitis, so monitoring is essential. Review labeling and clinic guidance before switching. See Beovu Pre Filled Syringe to compare presentation and dosing.

Device format also matters. Prefilled syringes can reduce preparation steps versus vials and support consistent dosing. Some practices choose vials for inventory flexibility. Discuss options with the treating retina specialist.

Combination Therapy

• With laser: Focal/grid laser may be used alongside anti-VEGF for DME or branch RVO, either sequentially or when retreatment intervals lengthen.
• With panretinal photocoagulation: Used for proliferative diabetic retinopathy to reduce neovascular drive, while anti-VEGF treats associated macular edema.
• Steroids: Intravitreal steroids may be reserved for select cases of DME or RVO, balancing cataract and pressure risks.
• Not mixed: Do not combine anti-VEGF agents in the same eye or syringe. Follow labeled guidance for each product.

Patient Suitability and Cost-Saving Tips

Candidates include adults diagnosed with wet AMD, DME, DR (including proliferative forms), macular edema after RVO, or mCNV, where anti-VEGF therapy is indicated. Patients should be able to attend follow-up injections and monitoring visits. Vision goals and comorbidities guide the plan.

Lucentis should not be used in those with active ocular or periocular infection, active intraocular inflammation, or known hypersensitivity to ranibizumab or excipients. Caution is warranted with a recent history of stroke or cardiovascular events. Discuss reproductive plans and systemic risk factors with a healthcare professional.

To help manage costs, clinics may consider multi-box orders when appropriate, coordinate reorders ahead of scheduled visits, and align appointments to reduce wasted product. CanadianInsulin offers prompt, express, cold-chain shipping to protect temperature-sensitive medicines. Enable simple reorder reminders so treatment is not delayed. For specific condition pages, see Diabetic Retinopathy and Myopic Choroidal Neovascularization. For deeper reading, visit How To Save On Monthly Lucentis Vial Orders From Canada.

Authoritative Sources

Genentech Lucentis product information

Health Canada Drug Product Database: ranibizumab

FDA Prescribing Information for Lucentis

Order Lucentis® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This page is educational and does not replace advice from your healthcare professional. Always follow your clinician’s instructions and the product’s official labeling.